$CSTL

MAETZOLD DEREK J sold $88K of CSTL (indirect holdings)

MAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 3,622 indirectly-held shares of CASTLE BIOSCIENCES INC (CSTL) at an average of $24.16 ($24.13–$25.06) across 12 trades on 2026-07-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MAETZOLD DEREK J
Published Jul 29, 2026, 8:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CSTL
Neutral
medium confidence
Mentioned
$CSTL
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CSTLNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around insider activity, but the pre-arranged nature and lack of additional company news limit the actionable impact.

02

Market read

New insider-sale disclosure for CSTL, with limited fundamental implications due to 10b5-1 pre-arrangement and no accompanying operational or financial update.

03

What to watch

Indirect ownership and multiple small trades across a price band may reflect administrative execution rather than a view on valuation or near-term fundamentals.

Relevance 2/10Novelty 5/10Timing: after-hours, new SEC Form 4 filed 2026-07-29 for 2026-07-27 sales

Background

The article is a primary-source SEC Form 4 disclosure for an insider transaction by CASTLE BIOSCIENCES CEO MAETZOLD DEREK J, executed under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$CSTLNeutralMedium confidence
Context

CASTLE BIOSCIENCES CEO MAETZOLD DEREK J sold $87,522.55 of CSTL via an open-market sale under a 10b5-1 plan on 2026-07-27.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional fundamental read from this single 10b5-1 sale.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 pre-arranged plan, which reduces the informational content versus discretionary selling. The article provides transaction size and price range but no accompanying company-specific catalyst.

Market effects

Minimal sector read-through; this is an issuer-specific insider sale with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

The sale could be purely liquidity-driven under the 10b5-1 plan and should not be treated as a bearish signal.

Key entities

  • CASTLE BIOSCIENCES INC

    Subject of the Form 4 insider transaction disclosure.

  • MAETZOLD DEREK J

    Pres. and Chief Exec. Officer; sold shares via open-market sale under a 10b5-1 plan.

Related articles

$CSTLMedAI 8/10

Castle Biosciences (CSTL) Q2 2026 Earnings Call Transcript

Castle Biosciences (CSTL) reported Q2 2026 total revenue of $103.5 million, up 20.1% from $86.2 million a year earlier, driven by TissueCypher volume and ASP gains. Management raised 2026 revenue guidance to $365 million to $375 million. Adjusted gross margin was 76.3% and adjusted EBITDA $12.4 million. Cash was $266.8 million at June 30, 2026.

$CSTLHigh

CASTLE BIOSCIENCES INC (CSTL): Results of Operations and Financial Condition

CASTLE BIOSCIENCES INC (CSTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026earningsre.htm EX-99.1 Document Exhibit 99.1 Castle Biosciences Reports Second Quarter 2026 Results Delivered Q2 2026 revenue of $103.5 million Q2 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 32